PACB - Director at Pacific Biosciences Acquires Company Stock Options Worth 86954 Shares | Benzinga
David Meline, Director at Pacific Biosciences (NASDAQ:PACB), reported a large acquisition of company stock options on October 16, according to a new SEC filing.
What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Meline, Director at Pacific Biosciences, a company in the Health Care sector, was just awarded stock options worth 86,954 shares of PACB. The options give Meline the right to buy the company's stock at $7.98 per share.
Pacific Biosciences shares are trading down 0.0% at $7.98 at the time of this writing on Tuesday morning. Since the current price is $7.98, this makes Meline's 86,954 shares worth $693,892.